6UT0

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Summary for 6UT0

Entry DOI	10.2210/pdb6ut0/pdb
Related	6USX 6USZ
Descriptor	GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (5 entities in total)
Functional Keywords	hydrolase inhibitor, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological source	Homo sapiens (Human)
Total number of polymer chains	4
Total formula weight	81705.70
Authors	Vigers, G.P.,Smith, D.J. (deposition date: 2019-10-29, release date: 2020-04-22, Last modification date: 2023-10-11)
Primary citation	Fell, J.B.,Fischer, J.P.,Baer, B.R.,Blake, J.F.,Bouhana, K.,Briere, D.M.,Brown, K.D.,Burgess, L.E.,Burns, A.C.,Burkard, M.R.,Chiang, H.,Chicarelli, M.J.,Cook, A.W.,Gaudino, J.J.,Hallin, J.,Hanson, L.,Hartley, D.P.,Hicken, E.J.,Hingorani, G.P.,Hinklin, R.J.,Mejia, M.J.,Olson, P.,Otten, J.N.,Rhodes, S.P.,Rodriguez, M.E.,Savechenkov, P.,Smith, D.J.,Sudhakar, N.,Sullivan, F.X.,Tang, T.P.,Vigers, G.P.,Wollenberg, L.,Christensen, J.G.,Marx, M.A. Identification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer. J.Med.Chem., 63:6679-6693, 2020 Cited by PubMed: 32250617 DOI: 10.1021/acs.jmedchem.9b02052 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.94 Å)

Structure validation